Bevespi Aerosphere 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
amended 
on 
II/0019/G 
This was an application for a group of variations. 
22/02/2024 
Annex II and 
Annex II has been updated as follows:  
B.II.d.1.e - Change in the specification parameters 
and/or limits of the finished product - Change 
outside the approved specifications limits range 
B.II.d.1.g - Change in the specification parameters 
PL 
• 
Delete AstraZeneca GmbH, Wedel, Germany from 
the list of the manufacturers responsible for batch release; 
Package Leaflet has been updated accordingly. 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
 
 
 
 
 
and/or limits of the finished product - Addition or 
replacement (excluding biological or immunological 
product) of a specification parameter wit its 
corresponding test method as a result of a safety or 
quality issue 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.II.c.1.c - Change in the specification parameters 
and/or limits of an excipient - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
B.II.c.2.d - Change in test procedure for an excipient 
- Other changes to a test procedure (including 
replacement or addition) 
PSUSA/10739
Periodic Safety Update EU Single assessment - 
30/11/2023 
n/a 
PRAC Recommendation - maintenance 
/202304 
glycopyrronium bromide / formoterol 
R/0017 
Renewal of the marketing authorisation. 
20/07/2023 
15/09/2023 
SmPC, Annex 
Based on the review of data on quality, safety and efficacy, 
II, Labelling 
the CHMP considered that the benefit-risk balance of 
and PL 
Bevespi Aerosphere in the approved indication remains 
Page 2/6 
 
 
 
 
 
 
 
 
 
PSUSA/10739
Periodic Safety Update EU Single assessment - 
01/12/2022 
n/a 
PRAC Recommendation - maintenance 
/202204 
glycopyrronium bromide / formoterol 
favourable and therefore recommended the renewal of the 
marketing authorisation with unlimited validity. 
N/0015 
Minor change in labelling or package leaflet not 
13/07/2022 
15/09/2023 
PL 
connected with the SPC (Art. 61.3 Notification) 
N/0013 
Minor change in labelling or package leaflet not 
11/05/2022 
15/09/2023 
Labelling and 
connected with the SPC (Art. 61.3 Notification) 
PL 
IA/0014 
A.7 - Administrative change - Deletion of 
24/03/2022 
n/a 
manufacturing sites 
PSUSA/10739
Periodic Safety Update EU Single assessment - 
02/12/2021 
n/a 
PRAC Recommendation - maintenance 
/202104 
glycopyrronium bromide / formoterol 
IA/0012/G 
This was an application for a group of variations. 
26/07/2021 
n/a 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
Page 3/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PSUSA/10739
Periodic Safety Update EU Single assessment - 
10/06/2021 
n/a 
PRAC Recommendation - maintenance 
/202010 
glycopyrronium bromide / formoterol 
IA/0009 
B.I.a.1.f - Change in the manufacturer of AS or of a 
02/12/2020 
n/a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
batch control/testing takes place 
PSUSA/10739
Periodic Safety Update EU Single assessment - 
26/11/2020 
n/a 
PRAC Recommendation - maintenance 
/202004 
glycopyrronium bromide / formoterol 
II/0006 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
17/09/2020 
16/07/2021 
SmPC, Annex 
Urinary tract infection (UTI) has been commonly reported 
new quality, preclinical, clinical or pharmacovigilance 
II, Labelling 
in several studies including glycopyrronium. Urinary tract 
data 
and PL 
infection is an expected ADR for other inhaled LAMA as 
well. UTI is therefore included as an adverse drug reaction 
in the SmPC, section 4.8 with the frequency common. The 
Patient Leaflet, section 4 is updated accordingly. 
IA/0008 
B.I.a.1.f - Change in the manufacturer of AS or of a 
28/07/2020 
n/a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
batch control/testing takes place 
PSUSA/10739
Periodic Safety Update EU Single assessment - 
14/05/2020 
n/a 
PRAC Recommendation - maintenance 
/201910 
glycopyrronium bromide / formoterol 
IB/0005 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
15/04/2020 
16/07/2021 
SmPC 
life of the finished product - As packaged for sale 
(supported by real time data) 
Page 4/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0004/G 
This was an application for a group of variations. 
08/04/2020 
n/a 
B.I.a.1.i - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Introduction of a new site of micronisation 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
PSUSA/10739
Periodic Safety Update EU Single assessment - 
31/10/2019 
n/a 
PRAC Recommendation - maintenance 
/201904 
glycopyrronium bromide / formoterol 
IB/0001/G 
This was an application for a group of variations. 
10/05/2019 
23/04/2020 
SmPC, Annex 
II, Labelling 
and PL 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
Page 5/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
responsible for importation and/or batch release - 
Not including batch control/testing 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
C.I.12 - Inclusion or deletion of black symbol and 
explanatory statements for medicinal products in the 
list of medicinal products that are subject to 
additional monitoring 
Page 6/6 
 
 
 
 
 
 
 
